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Sudden cardiac death still constitutes a major health problem 
despite the recent trend toward a decline in cardiovasculan 
mortality (1). The limitations and shortcomings of a tradi- 
tional preventive strategy with antiarrhythmic drugs in the 
treatment of patients with ischemic heart disease have been 
highlighted dramatically by the Cardiac Arrhythmia Sup- 
pressiou trial (CAST) study (2,3). The results of CAST and 
other studies (4) further underline the difference between 
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suppression of ventricular arrhythmias and prevention of 
sudden death. They also call attention to the need for 
pathophysiologic information gathered from relevant and 
specifically designed animal models. 
The relation between sympathetic nyperactivity and life- 
threatening arrhythmia has been demonstrated clearly O-9). 
This has resulted in the clinical use of beta-adrenergic 
blocking agents (10-12) or cardiac sympathetic denervaiion 
(13) to prevent sudden death in patients with a myocardia! 
infarction; however, the efficacy of beta-Mockers is i 
plete (approximately 25% reduction i 3 mortality), and 
patients are generally not considered candidates fo 
use. For instance, only 25% to 3% of ~05tmyocar~ia~ 
infarction patients enrolled in the CAST study were receiv- 
ing beta-blocker therapy (2). 
Recently, studies in a conscious i.nimal model (14) 
mented a correlation between indirec; lnarkers of high vagal 
tone (I 5) and powerful vagal reflexes ! 16.17) and a decreased 
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incidence ofsudden cardiac death. These markers also have 
prognostic value in humans (18-20). Ir was also shown in 
conscious dogs that vagal tone and reflexes do indeed 
provide protection against suddekl ath (21) and that elec- 
trical stimulation f the vagus nerve matically reduces the 
incidence ofventricular fibrillation during transient myocar- 
dial ischemia (22); however, limited information is
available with regard to must c agonists and malignant 
arrhythmias. 
The primary goal of the resent study was thcrefon to 
evaluate the potential antifibrillatory efficacy of a direct 
pharmacologic stimulation f the muscarinic receptors. The 
secondary goal was to assess the hemodynamic effects of 
two muscarinic agonists, methacholine prod oxotremorine, 
and to compare them with those of ;he beta-blocker p o- 
pranolol. Such a comparison was performed ina conscious 
animal model for sudden death in which dogs with a healed 
anterior myocardial infarction were subjected toa transient 
occlusion of the left circumflex coronary artery during 
exercise (14). Dogs that reproducibly developed ventricular 
fibrillation (“susceptible”) were utilized for the study. Pre- 
liminary results have been pFeSelIted elsewhere (23). 
Forty-four male mongrel dogs (15.9 kg. average weight) 
were used for the study. 
Surgical preparation. Anesthesia was induced with 
25 mg/kg intravenous thiopental sodium (Fa.rmotal, Farmi- 
talia) and was maintained bythe inhalation Gf a mixture of 
halothane, nitrous ox.ide aud oxygen. With aseptic proce- 
dures, a left thoracotomy was performed in the fourth 
intercostal space The pericardium was opened and the heart 
suspended in a cr dle. The l ft circumflex coronary artery 
was carefully dissected from surrounding epicardia1 fat, and 
both an electromagnetic flow transducer (Biotronex Labora- 
tory) and a hydraulic occluder were placed around the 
vessel. Ahigh fidelity Millar 5F microtip ressure transducer 
(MPC 500, Millar Instrumcntsj was inserted in the aortic 
arch and advanced to the left ventricle to record ventricular 
pressure. 
A Harris two-stage occlusion was performed on the left 
anterior descending coronary artery below the first diagonal 
branch to produce amyocardial infarction. The vessel was 
partially occluded for 20 min and then tied completely. 
All lead wires were tunneled under theskin to exit from 
the back of the dog. Intramuscular pentazocine lactate 
(Talwin, Winthrop Laboratories) (30 mg) was administered 
to control postoperative pain. We adhered to the guidelines 
of the American Physiological Society and the American 
Heart Association o  the care and treatment of experimental 
animals. 
EXperimenti proiocal, One month after production of 
myocardial infarction, the surviving animals were submitted 
t0 B submaximal exercise stress test. A catheter was placed 
in the jugular vein before the exercise and ischemia test. 
c.a.0. 
start exercise 
-Io~camlllglllB~~ stop 
0 3 6 9 12 15 18 20 
time (minutes) 
Rprr 1. Protocol of the exercise and ischemia test. The work load . .*> . 
is Increased every 3 mm until the ~LUI mm, first t!l b-w=vhw qneed J .jiC.ii~...c. . . 
(from 4.8 to 6.4 km/h), and then elevation o e treadmill (from C% 
to 12%). The drug is administered and the d run at a stable work 
load for 6 min; thereafter (18th min), the coronary artery occlusion 
(c.a.o.) is performed. The treadmill is stopped after Y min and t 
occlusion maintained for an additional I min. 
a slight modification, the exercise protocol followed 
escribed previously for this animal model (14) (Fig. 1). 
Briefly, the animals ran on a motor-driven tread 
19 min while the work load increased every 3 min (4.8 km/h, 
0% grade during the 1st 3 min; 6.4 kmlh, 12% grade during 
the last “I-min period). After I2 mill of exercise, the treat- 
ment drug was infused intravenously beginning ofthe 
last minute of exercise, the left circ coronary artery 
was occluded. The treadmill then was stopped, and the 
occlusion was maintained for an additional 1 min (total 
duration of occlusion 2min). Completeness of the occlusion 
was verified by the dia e phasic blood flow 
signal. Large steel plates were placed across the dog’s chest 
so that electrical defibrillation (HP 43120A, Hewlett- 
Packard) could be performed with minimal delay. 
Only the dogs that showed v ntricular fibrillation during 
the control exercise and ischemia test represent the subjects 
of the pharmacologic study (n = 11). In these dogs, subse- 
quent exercise and ischemia tests were performed with the 
following treatments, in a randomized sequence: 1) saline 
solution, 4 ml intravenously over 2 min, to confirm the 
reproducibility of the arrhythmia pattern (n = II); 2) prc+ 
pranolol, 1 mg/kg intravenously, over 2 min [r; .z 10); 
3) methacholine, 0.5 &kg per min by continuous int ave.. 
nous infusion beginning from the 12th min and throughorrt 
the coronary artery occlusion (n = 10); 4) oxotremorine, 
8 ,ug/kg intravenously over 2 min (n = 8). 
In the only dog that was not protected from ventricular 
IiCllation by propranolol (see Results), two further tests 
were performed. In the first, both propranolol and metha- 
choline (at the previously mentioned doses) were given; in 
the second, both propranolol and oxotremorine were given. 
Dogs were allowed to recover for at least 48 h after each 
trial to ensure acomplete return to baseline. This minimal 
period was increased to72 h after a test in wb~cb ve~~~c~~ar 
fibrillation occurred. The number of dogs studied with e 
various interventions differed because 1) one dog could not 
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Variable and Time 
NR (beatslmin) 
Wmin exercise 
30-s CAQ 
dP/dt,,, (mm i-&/s) 
Il-min exercise 
- 
Compound p $~ge” 
s P M 0 P YS. s M vs. s 0 vs. s ? vs. M P vs. 0 
203 2 33 165 ? 16 211 + 17 126 t 38 0.01 0.29 0.001 0.003 
218 t 32 167 2 30 249 2 21 141 2 58 0.09 @.!O 0.001 O.OOP 
168 c II 158 ” 18 174 2 12 161 t 17 0.11 0.30 0.23 0.02 9.74 
135 ” 20 116 + I8 145 + 11 145 + 18 0.027 0.17 0.14 O.EQ.2 
presented are mean values 1 I SD; CA0 = coronary artery occlusion: dP/dt,,, = maximal first derivative ofieh vemricuiar ~IT~SUI~; iiE = i~car’r fa.tc, L’v’F i 
left ventricular pressure; M = methacholiar; 0 = cxotiemorine; P = propranolol; S = saline solution. 
tended to cause a transient but significant increase in heart 
rate. Because with these bigher doses, 15 to 20 min is 
required for the reflex effect o subside (2% these doses 
would have required earlier start of 
influencing hemody during exerci 
markedly from the other treatment protoco 
at variance with oxotremor~~e~ was ~~mi~~stered as a clan- 
tinuous infusion owing to its susceptibility to cholinesterases 
(26). 
During each exercise and ischemia test, 
in the left c~r~~rn~ex coronary artery, left 
re, electrocardiogram and heart rate were 
made on an eight-channel polygraph recorder (Gould 38 
Gould Electronic!;). The signa& were also sampled at a r 
of 250 Hz, digitized with a multichannel analog/digital con- 
tt-Packard), fed into a Hewlett- 
) computerized system and stored 
ent analysis. The first derivative of
left ventricular p essure (dP/dt) was subsequently obtained 
line. 
naP minaret size. InLrct size was measured to 
obtain insights into the relation between the C!PJ~ tests and 
hemodynamics during acute myocardial ischemia. On com- 
pletion of the study, the dog was killed (barbiturate over- 
dose), the beart excised and infarct sizedetermi using a 
nitro blue tetrazohum enzymatic technique (27). By, the 
atria and right ventricular free wall were removed and the 
left ventricle was weighed. The infarct was then visually 
are two-tailed; a p v 
14at.a in the text are 
were chronically inst 
died in the 1st week p 
the implanted instrume 
e rerna~~i~g I I “susceptible” 
its. The hemodynamic values after drug in- 
fusion at 18 min and at 30 s after coronary t 
are show2 in Table 1, which also illustrates t 
scms among treatments. 
increased significan < MM) during exercise 
117 + 13 to 203 5 33 
increase after 30s of oc 
0.08). The tests with active treatment showed 
and well reproducible va
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Figilrii 2. Heari iaie vaiueS before atiri during ewcise in ik GNi 
treatment tests. The value at 12 min is just before drug administra- 
tion and that at 18 min is just before coronary artery occlusion 
(c.a.0.). Bars represent mean value t I SE. 
Figure 4. Values for maximal first derivative of left ventricular 
pressure (dP/dt max) before and during exercise in the four treat- 
ment tests. The value at 12 min is just before drug administration, 
that at 18 min is just before coronary artery occlusion (c.a.0.). 
represent mean value t I SE. 
within-animal 5.25%) untii the drug was added at the 12th 
min. After drug infusion (18 min of exercise), heart rate was 
significantly lower in the propranolol and oxotremorine 
groups, whereas it was unchanged in the methacholine group 
compared with both pretreatment and control values. At 
18 min of exercise, heart rate was significantly lower with 
oxotremorine than with propranolol. Thirty seconds after 
myocardial ischemia, no difference was observed in the 
methacholine test, whereas heart rate was lower in the 
propranoiol and ox&remorine tests compared with the saline 
test. At this stage, there was no difference between oxotrem- 
orine and propranofol. 
Left ventricular Fystolic pressure at the relevant stages of 
the exercise in the different treatment tests is shown in 
Figure 3. In the control trials, ventricular pressure increased 
during exercise from I48 2 lltol68rt IImmHg(p<O.Ol) 
and decreased during myocardial ischemia (I35 t 20 mm Hg 
after 30 s; p < 0.01). 
Propranolol-treated dogs showed a trend toward a reduc- 
tion in ventricular pressure before coronary artery occlu- 
sion; this was exacerbated by myocardial ischemia. After 
coronary artery occlusion, left ventricular pressure was 
significantly lower in the propranolol test than in the metha- 
choline and oxotremorine tests. Left ventricular pressure 
values after 30 s of ischemia were compared with the values 
at I2 min, just before drug infusion. A significantly greater 
pressure decrease (37 C 12%) was observed in the rano- 
lol test compared with the saline, metbacholine oxo- 
tremorine tests (I7 t 8%. I5 + 5% and I3 k 12%, respec- 
tively: p < 0.01). 
Maximal first derivative left ventricular pressure (dP/ 
dt,,,) values in the different tests are shown in Figure 4. 
the control trials. dP/dt,,,,,, increased during exercise from 
4.1162 t 625 to 6,621 + 695 mm Hgls (p < 0.01) and 
significantly decreased after 30 s of myocardial ischemia to 
4,226 + I.237 mm Hgls (p < 0.01). Before the occurrence of 
acute ischemia. this index of myocardial contractility was 
significantly depressed, compared with the value with saline 
solution, by propranolol and to a minor extent by oxotremo- 
rine. Indeed, dP/dt,,, values after propranolol were signif- 
icantly lower than after oxotremorine. During myocardial 
ischemia, the dP/dt,,, values in the propranolol test were 
significantly lower (approximately Xl%, p < 0.005 by anal- 
ysis of variance) than those of the three other tests, which 
were homogeneous. The dP/dt,,,, values after 30 s of isch- 
emia were compared with the values at I2 min, just before 
drug infusion. A significantly greater dP/dt decrease (63 2 
12%) was observed in the propranolol test compared with 
the saline, methacholine and oxotremorine tests (31 + l5%, 
25 t I I% and 28 + 24%, respectively, p < 0.01). 
Ventricular fibrillation. The efficacy of the different com- 
pounds in protectiug against ventricular fibrillation is shown 
in Table 2, and Figure 5 illustrates one example. Propranolol 
prevented the occurrence of ventricular fibrillation in all but 
one dog. The analysis, limited to the eight dogs that per- 
formed the saline solution and both muscarinic agonists 
tests, indicated that these drugs significantly influenced 
survival (p < 0.05 by Cochran’s Q test). The incidence of 
Figure 3. Left ventricular (Ventr.) pressure values before and 
during exercise in the four treatment tests. The value at I2 min is 
just before drug administration, that at I8 min is just before coronary 
artery occlusion (c.a.0.). Bars represent mean value + I SE. 
Placebo Propranolol Methacholine Oxotremorine 
I ~- 1 E?zz?m 
250 
a drug administration 
12 min 
i 
/ 
1 I i 
before exercise 18 min 30 set c.a.0. 
cororaary flow at 
fore ~~~~na~y rtery SC& 
nce was fouwd among 
e af ventricdx 
m 5. ‘I’ranslhorxic modified lead I e~~ct~~ca~~~a~~a~ 
ng and kit ventricular pressure (&VP) tracing of the four 
treatment tests in one dog. Ventricular ~~~l~a~i~~ occ 
the saline and the methacholine trials ==45 s after the 
coronary artery occlusion (c.a.0.). whereas 00 arrhythmia was 
observed in the propranolol and oxotremorine trials. Note the 
reduction in left ventricular pressure during ischeha in the pro- 
~~a.~~~101 test. 
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heart rate, it &as particularly important toassess whether 
this effect could be mediated by an increase in coronary 
flow; however, we found a mean total circumflex coronary 
flow of 45 -C 17 ml/min, a value similar to that in the saline 
tests (48 + 22 mUmin). 
iscnssion 
This study reports the effects of different pharmacologic 
autonomic nterventions in a established preparation that 
incorporates rhree factors important in the occurrence of
sudden cardiac death: a previous myocardial infarction, 
transient myocardial ischemia nd physiologically elevated 
sympathetic a tivity (30). 
protection from ventricular fibrillation may be achieved 
by pharmacologic interference with either limb of the auto- 
nomic nervous ystem, namely, either by blocking the 
sympathetic component or by enhancing the parasympa- 
thetic omponent. The data also reveal one important differ- 
ence. At the doses utilized, propranolol appeared tobe mo-e 
effective than methacholine and oxotremorine in protecting 
against ventricular fibrillation, but this greater efficacy was 
achieved at the cost of a marked impairment i  left ventric- 
ular contractility. 
Antifibrillatory effect. This animal model is particularly 
well suited for the comparative analysis of several interven- 
tions because of its very high internal reproducibility. The 
100% recurrence rate of ventricular fibrillation with saline 
solution in the present study matches well the previous 
observation f 92% recurrence of ventricular fibrillation i  a 
group of 24 dogs (22). 
Although the antifibrillatory effect of propranolol is for- 
mally reported for the first time in this animal model, it is in 
good agreement with previous unpublished data from our 
own laboratory and with a body of experimental and clinical 
work (6-8,11,12). Muscarinic agonists also significantly de- 
creased the incidence of ventricular fibrillation. This obser- 
vation represents animportant contribution tothe growing 
concept of a protective ffect of elevated vagal activity 
during myocardial ischemia (3 l-33). Different mechanisms 
may be involved in this beneficial effect. 
Parasympathetic activation has electrophysiologic effects 
on both automaticity (34,35) and refractoriness (36,37) in 
viva. Reflexly induced vagal hyperactivity may reproducibly 
terminate ventricular tachycardia in humans (38). Musca- 
rinic agonists may also antagonize the deleterious effects of 
sympathetic hyperactivity, acting at both presynaptic an 1 
postsynaptic levels (39,40). Acetylcholine r verts the short- 
ening in action potential duration i duced by isoproterenol irr 
hrkinje fibers and endocardium (41,42) and directly pro., 
kmgs action potential duration in the epicardium (42). 
The independence of these ffects from the modulation f 
existing beta-adrenergic tone remaiRs unsettled. Most stud- 
ies (8,36,43&I) suaest tha.t ventricular electrophysiologic 
effects of the vagua re mediated through an antiadrenergic 
activity, but evideuce (42,45,44) has been provided favog:lng 
a direct effect of the parasympatb~~ic nervous ystem on 
ventricular refractoriness. In the present study, only one dog 
was not protected by full-dose beta-blockade. The 
that the addition of either oxotrern~~~~e or metbach~~i~e 
could prevent ventricular fibrillation i this dog constitutes a 
limited but meaningful contribution tothe concept that the 
ct of vagal activation does not entirely 
A reduction in heart rate is by itself an ant~a~hyth~~ic 
mechanism. We recently assessed the contribution ofheart 
rate reduction to the ant~arrbythm~c effe t of vagal hyper- 
activity in different conditions. Vagal re 
blood pressure increase t completely abolis 
occurrence of ventricular ature complexes in
with chronic stable ventricular prematu 
When the heart rate decrease was prevente 
the decrease in the rate of ventricular 
plexes was clearly lower but still significant. In an acute 
feline preparation, oxotremorine significantly decrea the 
severity of life-threatening arrhythmia induced the 
combination of :ransient myo 
thetic hyperactivity, and thee 
heart rate was controlled (24 
scious canine preparation, vagal stimulation prevented ven- 
tricular fibrillation n 27 of the 30 susceptible 
(22); this effect persisted infive of nine dogs (55 
heart rate was corrected by atria1 pacing during acute 
myocardial ischemia. Overall, these studies indicate that 
heart rate reduction plays an important but not exclusive 
role in the antiarrhythmic and antifibrillatory effeci of vagal 
hyperactivity. 
Coronary vasodilation may occur in response to vagal 
hyperactivity (48) and may have contributed to the beneficial 
effect of muscarinic agonists; however, we were runable to
show an increase in left circumflex coronary artery blood 
flow before coronary occlusion. Although this finding does 
not exclude the possibility of a more favorable transmural 
gradient inblood flow, particularly after coronary occlusion, 
it does suggest that an increase in total coronary flow is 
r role in the antifibrillatory effect. 
ts. During the exercise and ischemia 
test, heart rate was significantly reduced by oxotremorine 
and propranolol but not by methacholine. Just before myo- 
cardial ischemia, heart rate was lower in the oxotremorine 
group than in the propranolol group; however, the response 
to coronary artery occlusion differed in the two tests be- 
cause heart rate increased in the former but not in the 
latter, suggesting the presence ofan increase in sympathetic 
activity whose ffects were completeiy blocked by proprano- 
lo1 and only partially counteracted by oxotremorine. Tbere- 
fore, heart rate during ischemia was not different inthe two 
tests. 
kropranolol caused a marked ecrease in dP/dt,,, that 
was reduced below the values Qbsc~cd incontrol con 
just before exercise. Conversely, oxotremorine produced a
slight decrease in contractility, whereas methacholine did 
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i result of 
after n0rma~izat~on of blood press endings imilar tQ 
those observed in our the dog (251, d0ses 
higher than those utihz caused a transient 
tachycardia; when earl rate r turned tocontrol values 20 ts 
30 min after the onset of infusion, the repetitive extrasystole 
threshold was found to be markedly increased, indicating 
that methacholine can exert an anti~b~~~a~ory e 
that have no effect on heart rate. 
Compared with methachohne, ox0tre 
much greater selectivity for adenylyl cyclase inhibition 
(51,521, suggesting that it binds preferentially t0 and 
mus:arinic receptors (53). This may account for gre 
hcsrt rate rednct~on. 
~~ne~~s~ons~ In this conscious canine erimental 
model for sudden cardiac death, beta-block with pro- 
pranolol was highly effective in preve 
lation. The muscarinic agonists oxot 
line showed a significant, althoug 
from sudden death. Compared with pro~rano~ol, these com- 
potmds caused much less impairment i  ventricular contrac- 
tility. 
Pharmacologic a tivation of the cardiac muscarinic re- 
ceptor may therefore represent a potentially new approach 
revention of sudden cardiac death, particularly when 
beta-blockers a e contraindicated and when negative inotro 
ic effects are to he avuided. 
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